Updated:
Symetis SA
Symetis SA was a Swiss medical device firm developing TAVI systems before Boston Scientific acquired it for $435M in 2017.
Symetis SA
Symetis SA was a privately held medical device company based in Ecublens, Switzerland, focused on the development and commercialization of transcatheter heart valve technologies. The firm was founded in 2011 by Dr. Hendrik Treede, Dr. Michael J. Mack, and Dr. Thomas Modine, among others, with a goal of offering a differentiated, self-expanding valve system for patients with aortic stenosis. Its ACURATE neo and ACURATE neo2 valves received CE Mark approval and were implanted in thousands of patients across Europe and other markets. The company’s strategy centered on direct sales and clinical evidence generation, with a focus on the transcatheter aortic valve replacement (TAVR) segment. Symetis maintained a strong presence in Europe and expanded into Asia and Latin America. Boston Scientific acquired Symetis in 2017 for approximately $435 million in cash, adding the ACURATE platform to its product portfolio. The deal closed in December 2017, and Symetis became part of Boston Scientific’s structural heart business. Post-acquisition, the ACURATE neo2 valve continues to be manufactured and distributed worldwide. Symetis contributed to a shift in the TAVI landscape, offering a lower profile delivery system and a self-expanding design with a supra-annular valve position. The company’s R&D activities remain integrated into Boston Scientific. No subsequent independent operational events are verifiable after the acquisition. The structural differentiator of Symetis was its focused mission: a pure-play TAVI developer with a proprietary valve design that specifically targeted clinical advantages in valve hemodynamics and patient outcomes, competing against larger, diversified players. Its acquisition by Boston Scientific reflected the ongoing consolidation in the structural heart market.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
Switzerland
City
Ecublens
Corporate office
Ecublens, Switzerland
Frequently asked questions
What did Symetis SA develop?
Symetis SA developed the ACURATE family of transcatheter aortic valve implantation (TAVI) systems, including the ACURATE neo and ACURATE neo2 valves. These devices were self-expanding, supra-annular bioprosthetic valves used to treat aortic stenosis.
Who acquired Symetis SA and for how much?
Boston Scientific acquired Symetis SA in December 2017 for approximately $435 million in cash. The acquisition was announced in February 2017 and closed later that year, integrating the ACURATE platform into Boston Scientific's structural heart portfolio.
Where was Symetis SA headquartered?
Symetis SA was headquartered in Ecublens, Switzerland, near Lausanne. The location supported the company's R&D and manufacturing operations for its heart valve technologies.
What happened to Symetis SA after the acquisition?
After the acquisition, Symetis SA became part of Boston Scientific's structural heart division. The ACURATE neo2 valve continues to be sold commercially, and the former Symetis facility in Switzerland operates as a key manufacturing and R&D site for Boston Scientific.
Was Symetis SA a publicly traded company?
No, Symetis SA was a privately held medical device company prior to its acquisition by Boston Scientific. It was funded by venture capital and private equity investors, including Edmond de Rothschild Investment Partners and others.
How did Symetis SA's TAVI valve differ from others?
Symetis's ACURATE platform featured a self-expanding design with a top-down deployment mechanism, a supra-annular valve position intended to optimize hemodynamic performance, and a low-profile delivery system. These features positioned it as a competitor to devices from Edwards Lifesciences and Medtronic.
Did Symetis SA have any notable clinical trials?
Symetis conducted clinical studies for the ACURATE valve, including the ACURATE IDE trial in the United States, which evaluated safety and effectiveness. The device received CE Mark approval in Europe, but the U.S. trial was ongoing at the time of the acquisition.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: